Clinical Trial Update: Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating adding cabozantinib to nivolumab versus standard chemotherapy for non-small cell lung cancer; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING